Sharemaestro Newsreel

Top Generate Biomedicines (GENB) Competitors 2026

Damora Therapeutics (DMRA) director awarded 30,350 stock options at $31.00 strike

Damora Therapeutics director Andrew Cheng was granted 30,350 stock options on August 12, 2026, with an exercise price of $31.00 per share and an expiration date of August 12, 2036. These options will vest in equal monthly installments through August 12, 2029, contingent on …

Damora Therapeutics (DMRA) files Form 3 for new director Andrew Cheng

Damora Therapeutics (DMRA) has filed a Form 3, an initial statement of beneficial ownership, for Andrew Cheng, identifying him as a new director. This filing officially establishes Cheng as a reporting person with the SEC, though it reports no stock transactions at this time. …

Is Kyntra Bio Inc (KYNB) Facing Challenges After Q2 Earnings Mis

4D Molecular Therapeutics (NASDAQ:FDMT) Announces Quarterly Earnings Results

Atrium Therapeutics Reports Second Quarter 2026 Financial Results

-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome -- -- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb -- SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," …

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Regeneron Pharmaceuticals Inc. (REGN) saw its stock price rally by 1.00% to $805.97, outperforming its competitors and the broader market on a strong trading day. This marked the stock's second consecutive day of gains, with the S&P 500 Index and Dow Jones Industrial Average …

Rani Therapeutics Holdings earnings beat by $0.01, revenue topped estimates

MacroGenics : Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position Announced sale of manufacturing operations ( July 2026) for $122.5 million and transition to fully outsourced model with leaner

MacroGenics reported its second quarter 2026 financial results, highlighting a significant corporate restructuring including the sale of its manufacturing operations for $122.5 million. This transition to a fully outsourced model has streamlined the company, reducing its workforce to approximately 140 people to focus on …

RYTM (NASDAQ: RYTM) investor plans sale of 5,079 shares worth $597K

An investor in Rhythm Pharmaceuticals (NASDAQ: RYTM) has filed a notice to sell 5,079 shares of common stock, valued at $597,290.40. The sale is planned through Morgan Stanley Smith Barney LLC on or after August 13, 2026, on NASDAQ. These shares originate from stock …

Lexeo Therapeutics (LXEO): Affinity Asset Advisors reports 8.4% beneficial stake

Affinity Asset Advisors, LLC and Michael Cho have reported an 8.4% beneficial stake in Lexeo Therapeutics (LXEO) through an amended Schedule 13G filing. This includes 6,674,913 shares of common stock, with 867,302 shares issuable upon warrant exercise, as of June 30, 2026. The reporting …

Moleculin Biotech (NASDAQ: MBRX) advances AML trial but warns on cash

Moleculin Biotech (NASDAQ: MBRX) is progressing with its pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed/refractory AML, showing promising preliminary efficacy and cardiac safety data. Despite these clinical advancements and a recent $9.3 million equity/warrant offering, the company reported a net loss of …

Ardelyx (ARDX) Is Down 19.1% After ESOP Shelf Filing And Higher 2026 Product Revenue Guidance

Ardelyx (ARDX) experienced a 19.1% stock drop following a US$36 million shelf registration for an ESOP and its Q2 earnings report. Despite a net loss, the company raised its 2026 IBSRELA revenue guidance to US$350–370 million, while reiterating XPHOZAH revenue expectations. This move signals …

Aktis Oncology (NASDAQ:AKTS) Posts Earnings Results, Meets Expectations

Aktis Oncology (NASDAQ:AKTS) recently reported its earnings, meeting the consensus estimate for EPS at ($0.44) and surpassing revenue expectations with $3.38 million. Despite the positive earnings surprise, the stock traded down 0.9% to $23.79, giving the company a market capitalization of approximately $1.27 billion. …

RYTM (RYTM) insider plans Form 144 sale of option and RSU shares

An insider at Rhythm Pharmaceuticals (RYTM) has filed a Form 144 indicating a proposed sale of 75,834 common shares through Morgan Stanley Smith Barney LLC. This total includes 56,601 shares from stock option exercises dated August 13, 2026, and 19,233 shares from Restricted Stock …

Elicio Therapeutics (ELTX) faces going-concern risk after $20M loss and trial miss

Elicio Therapeutics reported a net loss of $20.0 million for the first half of 2026 and faces substantial doubt about its ability to continue as a going concern, with existing cash expected to fund operations only into Q1 2027. The company's lead Phase 2 …

Tempest Therapeutics (TPST) expands CAR-T pipeline amid $32.9M loss and cash strain

Tempest Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Kyntra Bio: Q2 Earnings Snapshot

Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors

Tempest Therapeutics announced a collaboration with Senlang Biotechnology to advance its TPST-4003 in vivo CAR-T product candidates, targeting first patient dosing in late 2026 and initial clinical data in early 2027. The company also appointed Drake Richey and Dr. John Yee to its Board …

NEKTAR THERAPEUTICS ($NKTR) Releases Q2 2026 Earnings

Elicio Therapeutics: Q2 Earnings Snapshot

Alumis Inc. (ALMS) reports $235M loss but ends quarter with $502M cash

Rani Therapeutics (RANI) boosts liquidity with $20M raise and Chugai revenue

Moleculin Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Cibus (CBUS) narrows Q2 2026 loss as cash burn falls and regulatory tailwinds build

Nektar Therapeutics Announces Second Quarter 2026 Financial Results

Celcuity GAAP EPS of -$1.44 misses by $0.28

* Celcuity press release [https://seekingalpha.com/pr/20619145-celcuity-inc-reports-release-of-second-quarter-2026-financial-results-and-provides-corporate] (CELC [https://seekingalpha.com/symbol/CELC]): Q2 GAAP EPS of -$1.44 misses by $0.28. * Total operating expenses were $66.1 million for the second quarter of 2026, compared to $44.0 million for the prior year period. Research and development (“R&D”) expenses were $31.1 …

MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

MapLight Therapeutics has reported its financial results for Q2 2026, highlighting positive outcomes from its Phase 2 ZEPHYR trial for ML-007C-MA in schizophrenia, which is now advancing to Phase 3. The company is primarily focusing its resources on ML-007C-MA, with ongoing enrollment for the …

Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Eikon Therapeutics reported its second-quarter 2026 financial results, highlighting significant clinical advancements across its oncology portfolio, particularly with abstracts accepted for the ESMO Congress 2026. The company detailed progress in clinical trials for its drug candidates EIK1001, EIK1003, EIK1004, and EIK1005, and announced key …

Form 8K Tempest Therapeutics Inc For: 13 August By Investing.com

Investing.com reports that Tempest Therapeutics Inc. filed a Form 8K on August 13th. The article notes the company's stock symbol is TPST and indicates a -3.31% change. This brief report primarily serves as an announcement of the SEC filing.

Kyntra Bio (Nasdaq: KYNB) turns Q2 profit as deconsolidation gain offsets cash burn

Eikon Therapeutics (EIKN) reports $171.4M first-half loss and $531M cash

Yarrow Bioscience (VYNE) halves losses and completes transformative merger with Yarrow

Yarrow Bioscience (formerly VYNE Therapeutics) reported a significant reduction in its net loss for the six months ended June 30, 2026, dropping to $6.6 million from $14.4 million a year prior, largely due to decreased R&D spending as legacy programs were wound down. The …

Earnings Flash (ALMS) Alumis Inc. Reports Q2 Revenue $1.7M, Vs. FactSet Est of $3.5M

Alumis Inc. (ALMS) reported its second-quarter revenue, which came in at $1.7 million. This figure was significantly lower than FactSet's estimated revenue of $3.5 million, indicating a miss on analyst expectations for the quarter.

Earnings Flash (CELC) Celcuity Inc. Posts Q2 Adjusted Loss $1.07 per Share, vs. FactSet Est of $-1.12

Celcuity Inc. (CELC) reported a Q2 adjusted loss of $1.07 per share, which was better than the FactSet estimate of $-1.12 per share. The article, published on August 13, 2026, also noted that Celcuity's Q2 adjusted loss widened. This news follows several recent developments …